SOURCE: Geneart AG

April 09, 2010 01:09 ET

GENEART AG will become part of the US-Based Biotechnology Company Life Technologies Corp.

REGENSBURG, GERMANY--(Marketwire - April 9, 2010) -

Geneart AG / GENEART AG will become part of the US-Based Biotechnology Company Life Technologies Corp. processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.

- Life Technologies acquires 58 % of GENEART shares via itZs German subsidiary Applied Biosystems Deutschland GmbH

- Public tender offer for the remaining shares planned

- Cooperation Agreement concluded with Life Technologies

The founders of GENEART AG Prof. Dr. Ralf Wagner, Prof. Dr. Hans Wolf, Dr. Marcus Graf, and individual members of the management as well as the venture capital companies EquiNet EarlyStage Capital and S- REFIT AG, have signed contracts with Applied Biosystems Deutschland GmbH for selling their GENEART shares. Applied Biosystems Deutschland GmbH thus holds about 58 % of GENEART AG shares and is planning a voluntary public tender offer for the remaining GENEART AG shares. Applied Biosystems Deutschland GmbH is the German subsidiary of Life Technologies Corporation, a California/US biotechnology company with 2009 revenues of 3.3B U.S. dollar and about 9,000 employees. Furthermore, a cooperation agreement between GENEART AG and Life Technologies has been concluded.

For further inquiries, please contact:

Dr. Karoline Sturmer
GENEART AG
Josef-Engert-Str. 11
93053 Regensburg
Germany
Phone: +49-(0)941-942 76-417
Fax: +49-(0)941-942 76-711
ir@geneart.com
www.geneart.com


Frank Ostermair
Better Orange IR & HV AG
Haidelweg 48
81241 Munich
Germany
Phone: +49-(0)89-8896906-10
Fax: +49-(0)89-8896906-66
info@better-orange.de
www.better-orange.de

Legal Information:

This document may contain estimates, prognoses and opinions about company plans and objectives, products or services, future results, opinions about these results or opinions leading up to these results. All these projections into the future are subject to risk, uncertainty and unforeseeable change outside the control of the GENEART Group. Many factors may lead to actual results, which considerably deviate from the given projections for these results.



About GENEART AG:

In 2000 GENEART entered the Gene Synthesis market and has since become the global market leader. Today, the company is one of the leading specialists in the Synthetic Biology field. Experts at GENEART provide key technologies for the development and production of new therapeutics and vaccines. Customers also take advantage of GENEART services to customize enzyme attributes, such as the attributes of enzymes used as detergent additives, and to construct bacteria, which produce complex biopolymers or break down polymers, such as synthetics, petroleum components, etc. GENEART's service portfolio ranges from the optimization and production of synthetic genes according to DIN EN ISO 9001:2008, to the generation of gene variants or complex gene libraries and the production of cell lines, to the development and production of DNA and protein based drug candidates. GENEART AG in Regensburg and its subsidiaries GENEART Inc. in Toronto (Canada) and GENEART Inc. in San Francisco (USA) employ about 180 people. The company is listed on the German Stock Exchange since May 2006. Since April 2010, the US-American Life Technologies Corporation, one of the leading biotechnology companies worldwide with 2009 revenues of 3.3B U.S. dollars and about 9,000 employees, is majority shareholder of GENEART AG.


About Life Technologies Corporation:

Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of 3.3B U.S. dollar in 2009, employs approximately 9,000 people, has a presence in approximately 160 countries, and possesses a rapidly growing intellectual property estate of approximately 3,900 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc., and manufactures both in- vitro diagnostic products and research use only-labeled products. For more information on how we are making a difference, please visit our website: http://www.lifetechnologies.com.





[HUG#1401654]




Geneart AG
Josef-Engert-Str.11 Regensburg Germany

WKN: A0JJ4L;ISIN: DE000A0JJ4L4;

GENEART AG will become part of the US-Based Biotechnology Company Life Technologies Corp.: http://hugin.info/136633/R/1401654/356624.pdf

Contact Information